Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Mylan N.V.(NASDAQ:MYL)’s Generic Version Of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone Approved

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 04:16pm CET

A generic version of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone which has been developed by Mylan N.V.(NASDAQ:MYL) has been approved by the U.S. Food and Drug Administration. Copaxone is a blockbuster drug that is used in the treatment of multiple sclerosis.

The approval of the copaxone generic was a surprise to both Teva and Mylan since they had not been expecting it to happen so soon. This came a day after the FDA announced that measures would be introduced with a view to speeding up the approval of generics of complex drugs such as copaxone so that they can get to the market faster and assist in addressing the increasing cost of drugs.

Blockbuster drug

Copaxone is not only the leading therapy for multiple sclerosis in the world but is also the best-selling drug ever developed by Teva. Last year it generated revenues amounting to over $4 billion for the pharmaceutical giant headquartered in Tel Aviv, Israel.

According to Teva, the launch of the generic version of Copaxone was being done prior to the resolution of a couple of patent appeals. This implies that Mylan would end up paying significant damages in the event that Teva prevailed.

Two varying doses of the generic were approved by the FDA and this include the 40 mg dose and the 20mg dose. In this year’s second quarter, over 85% of the Copaxone prescriptions were made for the 40 mg dose.

Loss for Teva

According to analysts the approval amounted to a win for Mylan and a loss for Teva and projected that this would be reflected in both this year’s and next year’s earnings. Mylan’s first generic-version application for Copaxone was filed in 2009.

“Bottom line, this is incrementally positive for Mylan while for Teva both a negative surprise and a cash flow hit to 2018,” wrote Randall Stanicky, an RBC analyst, in a client note.

Two months ago U.S. Congress launched an investigation on drug pricing and Teva was among the pharmaceutical companies contacted over the cost of its multiple sclerosis drug. In 2017 the annual cost for the 20 mg dose of Copaxone is over $90,000 despite the fact that it was unveiled in 1996 and back then it used to cost approximately $8,000.

On Wednesday shares of Mylan N.V. rose by 16.20% to close the day at $37.80.

The post Mylan N.V.(NASDAQ:MYL)’s Generic Version Of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone Approved appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
02/23TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. Launch of QVAR® RediHaler™..
AQ
02/23TEVA PHARMACEUTICAL INDUSTRIES : Announces New Brand Positioning and Visual Iden..
AQ
02/22TEVA PHARMACEUTICAL INDUSTRIES : Announces New Brand Positioning and Visual Iden..
AQ
02/22United Therapeutics slips on further delays for RemoSynch
AQ
02/21TEVA PHARMACEUTICAL INDUSTRIES : Announces Exclusive Launch of Two Strengths of ..
AQ
02/20TEVA PHARMACEUTICAL INDUSTRIES : Announces Exclusive Launch of Two Strengths of ..
BU
02/16BERKSHIRE HATHAWAY : Cramer shocked by Buffett's investment in "second-rate" Tev..
AQ
02/16NOVARTIS : FDA Approves Another New Generic Form of 40mg Copaxone
AQ
02/16Backstory - Warren Buffett's Valentine's Day surprise for investors
RE
02/16BACKSTORY : Warren Buffett's Valentine's Day surprise for investors
RE
More news
News from SeekingAlpha
02/24TEVA : Berkshire Thinks Bondholders Are 'Mullet Mullet' 
02/24Patent Office Puts Allergan's Mohawk Deal Out Of Its Misery 
02/23Assessing Changes In Berkshire Hathaway Holdings 
02/22Is Teva A Falling Drug Company Or A Great Value Proposition 
02/22ACETO : Collapsing Generic Drug Pricing Brings Risk Of Covenant Violations 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 1,03x
Capi. / Sales 2019 1,04x
Capitalization 20 184 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 18,5 $
Spread / Average Target -7,1%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED7.76%20 184
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618